文献速递创伤与烧伤复苏、休克与脓毒症

主动脉复苏性血管内球囊阻断术死亡率增加仅能被强未测量混杂因素抵消:基于国家创伤数据库的扩展分析

Increased mortality with resuscitative endovascular balloon occlusion of the aorta only mitigated by strong unmeasured confounding: An expanded analysis using the National Trauma Data Bank.
PubMed 文献 · J Trauma Acute Care Surg · 2021-01-01
一句话结论在TQIP数据中,REBOA与死亡率升高相关(风险差0.21),该效应只能被强于任何已观测因素的未测量混杂因素抵消。

本研究为回顾性分析,使用2015至2017年TQIP数据库,纳入年龄大于18岁、到达时存在生命体征、无主动脉损伤且未转运的患者,排除2小时后置入的REBOA。共1,392,482例符合标准,其中187例接受REBOA。采用倾向性评分逆概率治疗加权调整基线变量后,死亡风险差为0.21(0.14-0.29),急性肾损伤风险差为0.041(-0.007至0.089)。敏感性分析显示,要解释死亡效应,未测量混杂因素需强于任何已观测因素。11例REBOA患者接受下肢截肢,但均存在严重下肢创伤。结论认为TQIP数据无证据提示REBOA导致截肢,其对AKI影响的证据较既往报告明显减弱,而死亡率增加效应被证实。

要点

  • 在2015至2017年TQIP数据中,187例接受REBOA的患者经逆概率加权后死亡风险差为0.21(0.14-0.29),提示死亡率增加。
  • REBOA与急性肾损伤的风险差为0.041(-0.007至0.089),95%CI跨0,未达统计学显著。
  • 敏感性分析表明,只有强于任何已观测因素的未测量混杂因素才能将REBOA的死亡效应抵消为零。
  • 11例REBOA患者接受下肢截肢,但均存在严重下肢创伤,数据不提示REBOA导致截肢。
  • 研究证据等级为治疗/管理类,level IV。

适用人群与场景

  • 2015至2017年TQIP数据库中年龄大于18岁、到达时存在生命体征、无主动脉损伤且未转运的创伤患者。
  • 排除2小时后置入的REBOA。

研究设计与关键结果

  • 回顾性研究,使用2015至2017年TQIP数据库,共1,392,482例符合纳入标准,其中187例接受REBOA。
  • 采用倾向性评分逆概率治疗加权调整基线变量,加权后所有协变量均衡。
  • 死亡风险差为0.21(0.14-0.29);急性肾损伤风险差为0.041(-0.007至0.089)。
  • 敏感性分析:要解释死亡效应,未测量混杂因素(如未测量的休克严重程度/复苏反应)需强于任何已观测因素与其和死亡率及REBOA置入的关系。
  • 11例REBOA患者接受下肢截肢,但均遭受严重下肢创伤。

证据类型、等级与局限

  • 证据类型:回顾性研究;证据等级:治疗/管理,level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为TQIP数据无证据提示REBOA导致截肢,REBOA对急性肾损伤影响的证据较既往报告明显减弱。
  • 作者认为REBOA的死亡率增加效应被证实,且只能被强效混杂因素抵消。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Resuscitative endovascular balloon occlusion of the aorta (REBOA) is being increasingly adopted to manage noncompressible torso hemorrhage, but a recent analysis of the 2015 to 2016 Trauma Quality Improvement Project (TQIP) data set showed that placement of REBOA was associated with higher rates of death, lower extremity amputation, and acute kidney injury (AKI). We expand this analysis by including the 2017 data set, quantifying the potential role of residual confounding, and distinguishing between traumatic and ischemic lower extremity amputation.

METHODS: This retrospective study used the 2015 to 2017 TQIP database and included patients older than 18 years, with signs of life on arrival, who had no aortic injury and were not transferred. Resuscitative endovascular balloon occlusions of the aorta placed after 2 hours were excluded. We adjusted for baseline variables using propensity scores with inverse probability of treatment weighting. A sensitivity analysis was then conducted to determine the strength of an unmeasured confounder (e.g., unmeasured shock severity/response to resuscitation) that could explain the effect on mortality. Finally, lower extremity injury patterns of patients undergoing REBOA were inspected to distinguish amputation indicated for traumatic injury from complications of REBOA placement.

RESULTS: Of 1,392,482 patients meeting the inclusion criteria, 187 underwent REBOA. After inverse probability of treatment weighting, all covariates were balanced. The risk difference for mortality was 0.21 (0.14-0.29) and for AKI was 0.041 (-0.007 to 0.089). For the mortality effect to be explained by an unmeasured confounder, it would need to be stronger than any observed in terms of its relationship with mortality and with REBOA placement. Eleven REBOA patients underwent lower extremity amputation; however, they all suffered severe traumatic injury to the lower extremity.

CONCLUSION: There is no evidence in the TQIP data set to suggest that REBOA causes amputation, and the evidence for its effect on AKI is considerably weaker than previously reported. The increased mortality effect of REBOA is confirmed and could only be nullified by a potent confounder.

LEVEL OF EVIDENCE: Therapeutic/care management, level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Linderman GC, Lin W, Becher RD, et al. Increased mortality with resuscitative endovascular balloon occlusion of the aorta only mitigated by strong unmeasured confounding: An expanded analysis using the National Trauma Data Bank. J Trauma Acute Care Surg. 2021. PMID: 33951027. doi:10.1097/TA.0000000000003265

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。